Trial Profile

A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Serdexmethylphenidate (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Adverse reactions; Registrational
Sponsors Zevra Therapeutics

Most Recent Events

26 Jun 2023 Results presented in the Corium Media Release.
26 Jun 2023 According to a Corium media release, results of a yearlong open-label safety study were published in the peer-reviewed journal Frontiers in Psychiatry.
22 May 2023 According to a Corium media release, a new analysis from this study published in the Journal of Child and Adolescent Psychopharmacology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com